Lorillard, Inc. (NYSE:LO) will unveil its latest earnings on Thursday, February 9, 2012. The average estimate of analysts is for profit of $1.96 per share, a rise of 12.6% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. For the year, analysts are projecting net income of $7.65 per share, a rise of 12.8% from last year.

Last quarter, the company missed estimates by 10 cents, coming in at profit of $1.94 per share versus a mean estimate of net income of $2.04 per share. In the second quarter, the company beat estimates by 3 cents. On average, analysts predict $1.08 billion in revenue this quarter, a rise of 5.9% from the year ago quarter. Analysts are forecasting total revenue of $4.24 billion for the year, a rise of 4.7% from last year’s revenue of $4.05 billion.

Competitors to Watch: Reynolds American, Inc. (NYSE:RAI), Altria Group, Inc. (NYSE:MO), Vector Group Ltd. (NYSE:VGR), Philip Morris Intl. Inc. (NYSE:PM), British American Tobacco (AMEX:BTI), Star Scientific, Inc. (NASDAQ:CIGX), Alliance One Intl., Inc. (NYSE:AOI), and Universal Corporation (NYSE:UVV).

Prestige Brands Holdings, Inc. (NYSE:PBH) will unveil its latest earnings on Thursday, February 9, 2012. The average estimate of analysts is for net income of 24 cents per share, a rise of 20% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. For the year, analysts are projecting profit of 96 cents per share, a rise of 21.5% from last year.

The company has met estimates the last three quarters. Last quarter, the company reported net income of 26 cents per share to fall in step with the mean estimate. On average, analysts predict $103.8 million in revenue this quarter, a rise of 14.6% from the year ago quarter. Analysts are forecasting total revenue of $418.7 million for the year, a rise of 24.4% from last year’s revenue of $336.5 million.

Competitors to Watch: The Procter & Gamble Co. (NYSE:PG), Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), Perrigo Company (NASDAQ:PRGO), Watson Pharmaceuticals, Inc. (NYSE:WPI), Hi-Tech Pharmacal Co. (NASDAQ:HITK), Allergan, Inc. (NYSE:AGN), GlaxoSmithKline plc (NYSE:GSK), and Akorn, Inc. (NASDAQ:AKRX).

Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!